Hyperlipidemia. Disorders of lipoprotein metabolism and other lipidaemias
Conditions
Interventions
Intervention 1: Intervention group will be administered with15cc Persian walnut (Juglans regia L.) oil, per day, for 90 days. Intervention 2: Control group will be received placebo (distilled water ca
Treatment - Drugs
Placebo
Intervention group will be administered with15cc Persian walnut (Juglans regia L.) oil, per day, for 90 days.
Control group will be received placebo (distilled water capsule) per day, for 90 days.
Sponsors
Shiraz University of Midical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Patients with diagnosed type2 diabetes for at leat 2 years and also with either plasma TG level more 150 mg/dL or total cholestrol level more 200 mg/dL or LDL between 130-200 or HDL less 50 in female and less 40 in male; Patients who received maximum 2 oral diabetes medications. Exclusion Criteria: Patients who have a history of chronic or metabolic diseases, or regularly use medication (Fibrate and HMG-COA Reductase inhibitor) or supplements known to affect blood lipids; Patients who have to receive antihyperlipidemic agents for example CAD patients; Patients who were currently received insulin therapy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Triglyceride. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique).;Low-density lipoprotein (LDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique).;High-density lipoprotein (HDL). Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (dextran magnesium sulfate).;Total cholesterol. Timepoint: Before and 3 months after intervention. Method of measurement: Biochemical measurements on blood sample (GPA-PAP technique). | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: Before and 2 months after intervention. Method of measurement: By BMI Formula.;Systolic Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer.;Diastol Blood Pressure. Timepoint: Before and 3 months after intervention. Method of measurement: Mercury sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.pouya Farhadi
Shiraz University of Medical Sciences
Outcome results
None listed